Why the study?
HTG management is important for preventing acute pancreatitis and managing ASCVD risk, but mechanisms of EPA and integration with other therapies remain to be established.
The management of hypertriglyceridemia is evolving, with a focus on understanding EPA's cardiovascular benefits and awaiting data on novel therapies.
HTG management for pancreatitis prevention and ASCVD risk remains incompletely defined; leaves open EPA mechanisms and novel therapy outcomes.
The clinical management of HTG is important in the prevention and treatment of acute pancreatitis and also impacts on how ASCVD risk is managed. More work needs to be done to establish the mechanism for the ability of how EPA lowers ASCVD and how to best integrate it with other lipid-lowering therapies. The efficacy and safety of the novel therapies for HTG should be established soon in the ongoing late-stage clinical trials.
No takes yet. Share an insight, caveat, or question.
Wolska et al. (2020) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: